AMPK and Polycystic Kidney Disease Drug Development: An Interesting Off-Target Target

13Citations
Citations of this article
10Readers
Mendeley users who have this article in their library.

Abstract

Autosomal Dominant Polycystic Kidney Disease is a genetic disease that causes dramatic perturbations of both renal tissue architecture and of a multitude of cellular signaling pathways. The relationship between the products of the genes whose mutations cause polycystic kidney disease and these signaling pathways remains difficult to determine. It is clear, however, that cellular metabolism is dramatically altered in cells that are affected by polycystic kidney disease mutations. Adenosine monophosphate-stimulated protein kinase is a master regulator of cellular energy use and generation pathways whose activity appears to be perturbed in cells affected by polycystic kidney disease. Furthermore, modulation of this enzyme's activity may constitute a promising approach for the development of new therapeutics for polycystic kidney disease.

Cite

CITATION STYLE

APA

Caplan, M. J. (2022, January 31). AMPK and Polycystic Kidney Disease Drug Development: An Interesting Off-Target Target. Frontiers in Medicine. Frontiers Media S.A. https://doi.org/10.3389/fmed.2022.753418

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free